Tackling the Disparities in the Management of Atopic Dermatitis in African Americans: The Time is Now
Atopic dermatitis (AD) is a chronic inflammatory and relapsing cutaneous disease characterized by pruritus, cutaneous inflammation, and transepidermal water loss (Krakowski 2008). The incidence of AD in industrialized nations has increased by 2- to 3-fold over 30 years– it is estimated to affect between 15% and 30% of children in industrialized nations and up to 10% of adults (Bieber 2010; Silverberg 2013). The economic burden associated with AD is significant, with direct health care costs and indirect costs, such as those associated with missed work, estimated at $1000 per patient annually in the United States, and total estimated annual costs of $5.297 billion in 2015 (Drucker 2017; Mallett 2007).
The increasing incidence of AD and poor recognition of the disease in some patient groups is a public health concern. Also, there are disparities in the diagnosis and management of African Americans ( Cohen 2020). AD symptoms and its daily management cause significant effects on quality of life for both patients and caregivers. AD is associated with an increase in other atopic manifestations as well as with serious comorbidities that can significantly affect overall patient health and wellbeing (Silverberg 2015; Simpson 2012; Yu 2016; Zheng 2011).
There have been mounting evidence suggesting the involvement of intricate interactions between genetic, environmental as well as lifestyle factors as a causal factor for atopic dermatitis (Cohen 2020). Many times, these modifiable external factors and surrounding environments might contribute to disparities in prevalence, severity, management, and quality of care among different racial and ethnic groups. Therefore, it is pertinent to educate clinicians about differences in AD between African Americans and other populations, which might be essential for the development personalized and tailored treatment regimens, as an important step to address these ongoing gaps.
Recognizing our role in reducing these disparities, LiVDerm aims to educate clinicians and care teams – evidence-based prevention and treatment plans, especially in the community where most health is affected to enhance the care of patients from different racial and ethnic groups.
This activity is designed for an audience of physicians, nurses, pharmacists, and professional staff members of medical practices specializing in dermatology and allergy/immunology.
- Identify approaches for improving the prevention and assessment of AD among African American population, including performing a comprehensive assessment of AD impacts on patients’ quality of life
- Develop strategies that will aid targeted treatment of AD in this population
|I.||Introduction: Evaluating the Burden of AD in African Americans|
|II.||Factors Contributing to Care Disparities in African American Population|
|III.||Evaluating and Screening for AD in AA Patients|
|IV.||Patient Case Evaluation: Strategies for Diagnosing and Treating AD in AA Patients|
|V.||Optimizing AD treatment in African American population|
Andrew F. Alexis, MD, MPH
New York, New York
Nanette B. Silverberg, MD
New York, New York
Peter A. Lio, MD
Clinical Assistant Professor of Dermatology and Pediatrics
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires all individuals who are in a position to control the content of this activity to disclose all their financial relationships with ineligible companies. All identified COI are thoroughly mitigated according to the Annenberg Center for Health Sciences at Eisenhower’s policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Name of Faculty or Presenter
Reported Financial Relationship
Andrew F. Alexis, MD, MPH
Royalties: Springer, Wiley-Blackwell, Wolters KltMer
Consulting: Leo, Galderma, Pfizer, sanofi-Regeneron, Dermavant, Beiersdorf, Valeant, L’Oreal, BMS, Bausch Health, UCB, Vyne, Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel, Amgen
Speaker: Regeneron, SANOFI-Genzyme, Pfizer, AStra Zeneca
Contracted Research: Leo, Novartis, Almirall, Bristol-Myers Squibb, Amgen, Menlo, Galderma, Valeant, Cara, Arcutis
Peter Lio, MD
Speaker: Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, LEO, Galderma, and L'Oreal
Advisory Board: Almirall, ASLAN, Dermavant, Regeneron/Sanofi, Pfizer, LEO, AbbVie, Eli Lilly, L’Oreal, Unilever
Research: AOBiome, Regeneron/Sanofi Genzyme, Eli Lilly, and AbbVie
Patent Holder: Theraplex AIM (Patent Pending)
Stockholder: Micreos, YobeeCare, and Altus Labs, KPAway
Nanette Silverberg, MD
Consultant: Verrica, Vyne
Speaker: Regeneron, Sanofi
The planners and others reported the following financial relationships or other relationships they have with ACCME-defined ineligible companies related to the content of this continuing education activity:
The PIM planners and others have nothing to disclose.
All staff at the Annenberg Center for Health Sciences at Eisenhower involved in this activity have no relationships to disclose.
The content manager, Amy Kousouros, from LivDerm, has nothing to disclose.
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and LivDerm in collaboration with Postgraduate Institute for Medicine.
Estimated time to complete activity: 1 hour
This activity is supported by an educational grant from Incyte.
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and LivDerm. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™️. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
1 contact hour may be earned for successful completion of this activity.
Pharmacist Continuing Education
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program has been developed according to the ACPE Criteria for Quality and is assigned ACPE Universal Activity #0797-9999-21-106-H01-P. This program is designated for up to 1 contact hours (0.1 CEUs) of continuing pharmacy education credit.
Type of Activity: Application
Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.
A computer or device with an internet connection.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.